去势抵抗型前列腺癌雄激素代谢及新生的研究进展

Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer

前列腺癌(PCa)经雄激素剥夺治疗(ADT)后普遍进展为去势抵抗型前列腺癌(CRPC),其可能的机制除了AR的扩增、突变及其信号通路的激活外,还与雄激素代谢途径的改变相关。本文综述近年来有关CRPC肿瘤内雄激素含量的改变,及引起这些改变的原因包括雄激素新生、雄激素合成代谢酶活性变化、雄激素合成代谢酶的转运效率的改变以及肿瘤微环境相互作用的改变及其临床应用价值的最新研究进展。

Prostate cancer generally relapses into castration resistant prostate cancer （CRPC） after androgen deprivation therapy, which may be associated with androgen metabolism, particularly de novo androgen synthesis apart from the amplification and mutation of androgen receptor and the activation of its signaling pathways. This article focuses on the advances in the studies of the changes in androgen metabolism and de novo androgen synthesis in CRPC as well as their possible mechanisms and clinical significance.